All articles by Srivani Venna

  1. Pfizer’s trial of Revatio fails to meet primary endpoint

    Pfizer’s Phase III study of intravenous (IV) sildenafil (Revatio) added to inhaled nitric oxide (iNO) to treat newborns with Persistent…
    Read More…

    1 Jul
  2. AstraZeneca reports positive results from CASPIAN trial of Imfinzi

    AstraZeneca’s human monoclonal antibody Imfinzi (durvalumab) has improved overall survival in the Phase III CASPIAN trial in first-line extensive-stage small…
    Read More…

    28 Jun
  3. Acceleron completes enrolment for PULSAR trial of sotatercept

    Acceleron Pharma has completed enrolment for the PULSAR Phase II trial of sotatercept to treat patients with pulmonary arterial hypertension…
    Read More…

    28 Jun
  4. Lilly reports positive results from trial of diabetes drug Trulicity

    Eli Lilly and Company has reported that the AWARD-11 Phase III trial of Trulicity (dulaglutide) met its primary efficacy endpoint…
    Read More…

    27 Jun
  5. ILiAD initiates Phase IIb trial of pertussis vaccine BPZE1

    ILiAD Biotechnologies has initiated the Phase IIb IB-200P clinical trial of BPZE1, a live attenuated intranasal vaccine to treat pertussis,…
    Read More…

    27 Jun
  6. BioPharmX reports positive results from BPX-041 trial for rosacea

    BioPharmX has reported positive results from its Phase IIb trial of BPX-041 for the treatment of moderate-to-severe papulopustular rosacea, a…
    Read More…

    26 Jun
  7. Asieris concludes enrolment for Phase Ib trial of APL-1202

    Chinese biotech company Asieris Pharmaceuticals has completed enrolment for its Phase Ib trial in the US to evaluate the safety,…
    Read More…

    26 Jun
  8. BMS’ trial of HCC drug fails to meet primary endpoint

    Bristol-Myers Squibb’s (BMS) CheckMate -459 Phase III clinical trial of Opdivo (nivolumab) versus sorafenib in patients with unresectable hepatocellular carcinoma…
    Read More…

    25 Jun
  9. FDA lifts partial clinical hold on AbbVie’s trial of venetoclax

    The US Food and Drug Administration (FDA) has lifted the partial clinical hold placed on AbbVie’s CANOVA (M13-494), a Phase…
    Read More…

    25 Jun
  10. Motif Bio unveils new iclaprim data for skin disorders

    Motif Bio has presented new data for antibiotic drug candidate iclaprim at the American Society for Microbiology (ASM) Microbe 2019…
    Read More…

    25 Jun
Close
Close
Close

Go Top